Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba
التنسيق: مقال
اللغة:English
منشور في: SAGE Publishing 2016-03-01
سلاسل:Therapeutic Advances in Gastroenterology
الوصول للمادة أونلاين:https://doi.org/10.1177/1756283X15621232

الانترنت

https://doi.org/10.1177/1756283X15621232

مواد مشابهة